New spinal injection drug enters first human test for early Alzheimer's
NCT ID NCT05231785
Summary
This early-stage study is testing the safety and effects of a new drug called ALN-APP for people with early-onset Alzheimer's disease. The drug is given as an injection into the spinal fluid. Researchers will monitor 60 participants to see how their bodies handle the drug and check for changes in Alzheimer's-related proteins in their spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY ONSET ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
COMPLETEDLa Jolla, California, 92037, United States
-
Clinical Trial Site
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Clinical Trial Site
RECRUITINGMontreal, H3A 2B4, Canada
-
Clinical Trial Site
RECRUITINGToronto, M3B 2S7, Canada
-
Clinical Trial Site
RECRUITINGAmsterdam, 1081 BT, Netherlands
-
Clinical Trial Site
COMPLETEDGroningen, 9713 GG, Netherlands
-
Clinical Trial Site
RECRUITINGHuntley Street, WC1E 6AG, United Kingdom
-
Clinical Trial Site
RECRUITINGSheffield, S10 2JF, United Kingdom
Conditions
Explore the condition pages connected to this study.